Oruka Therapeutics (NASDAQ:ORKA) Stock Rating Reaffirmed as Outperform by Wedbush

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “outperform” rating reissued by research analysts at Wedbush in a research report issued to clients and investors on Tuesday, Benzinga reports. They presently have a $165.00 price objective on the stock. Wedbush‘s price target suggests a potential upside of 73.81% from the stock’s previous close.

Several other equities analysts also recently commented on the company. Piper Sandler reaffirmed an “overweight” rating on shares of Oruka Therapeutics in a research report on Wednesday, October 7th. HC Wainwright reissued a “buy” rating on shares of Oruka Therapeutics in a research note on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Tuesday, October 13th. BTIG Research reiterated a “buy” rating and set a $151.00 price objective on shares of Oruka Therapeutics in a report on Monday, October 19th. Finally, Wall Street Zen cut shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 16th. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Oruka Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $133.00.

Oruka Therapeutics Stock Up 5.1%

NASDAQ:ORKA traded up $4.60 during mid-day trading on Tuesday, hitting $94.93. 774,188 shares of the stock traded hands, compared to its average volume of 1,085,240. Oruka Therapeutics has a 52 week low of $25.23 and a 52 week high of $115.51. The stock has a market capitalization of $6.29 billion, a price-to-earnings ratio of -46.76 and a beta of -0.37. The firm’s 50 day moving average is $89.99 and its two-hundred day moving average is $67.22.

Oruka Therapeutics (NASDAQ:ORKA) last announced its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04). As a group, research analysts predict that Oruka Therapeutics will post -2.42 EPS for the current year.

Insider Buying and Selling at Oruka Therapeutics

In other news, insider Joana Goncalves sold 7,947 shares of the stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $92.38, for a total transaction of $734,143.86. Following the transaction, the insider directly owned 31,771 shares in the company, valued at approximately $2,935,004.98. This trade represents a 20.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Arjun Agarwal sold 10,000 shares of Oruka Therapeutics stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $106.66, for a total transaction of $1,066,600.00. Following the transaction, the senior vice president directly owned 15,312 shares in the company, valued at approximately $1,633,177.92. The trade was a 39.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 154,950 shares of company stock valued at $14,102,680. Company insiders own 23.49% of the company’s stock.

Institutional Trading of Oruka Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of ORKA. Nykredit A S bought a new stake in Oruka Therapeutics during the 2nd quarter valued at $29,000. GAMMA Investing LLC raised its position in shares of Oruka Therapeutics by 201.6% in the 3rd quarter. GAMMA Investing LLC now owns 374 shares of the company’s stock worth $31,000 after acquiring an additional 250 shares in the last quarter. Orion Capital Management LLC purchased a new stake in shares of Oruka Therapeutics during the 2nd quarter worth $91,000. Sterling Capital Management LLC lifted its stake in shares of Oruka Therapeutics by 839.0% during the 3rd quarter. Sterling Capital Management LLC now owns 1,662 shares of the company’s stock worth $138,000 after purchasing an additional 1,485 shares during the last quarter. Finally, Royal Bank of Canada boosted its position in Oruka Therapeutics by 178.5% during the first quarter. Royal Bank of Canada now owns 3,172 shares of the company’s stock valued at $155,000 after purchasing an additional 2,033 shares in the last quarter. Institutional investors own 56.44% of the company’s stock.

Trending Headlines about Oruka Therapeutics

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Oruka reported positive Week 16 results from the Phase 2b EVERLAST-B trial in moderate-to-severe psoriasis. In the 600 mg high-dose group, 61% of patients achieved complete skin clearance (PASI 100), while 86% achieved PASI 90. The company said the efficacy was highly similar to the earlier EVERLAST-A study, with a favorable safety and tolerability profile consistent with the IL-23p19 drug class. Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001
• Positive Sentiment: The data prompted substantial market optimism, with reports highlighting the 61% complete-clearance rate and describing ORKA-001 as potentially differentiated in psoriasis. Guggenheim reportedly estimated the treatment could generate as much as $7 billion in peak sales, increasing the perceived value of Oruka’s pipeline. Oruka’s psoriasis treatment could generate $7B in peak sales
• Positive Sentiment: Management expects ORKA-001 to enter Phase 3 trials in the first half of 2027. Additional catalysts include 52-week EVERLAST-A results expected in December 2026 and ORKA-002 Phase 2 psoriasis results expected in the first quarter of 2027. Oruka Therapeutics trial update
• Positive Sentiment: Wedbush reaffirmed its “outperform” rating and assigned a $165 price target, implying significant upside from the stock’s recent level and reinforcing the bullish analyst view. Wedbush stock recommendations
• Neutral Sentiment: Reported short interest was listed at zero shares as of October 26, producing a zero-day days-to-cover ratio. This suggests short covering is unlikely to be a major explanation for the move, although the data may reflect a reporting anomaly.

About Oruka Therapeutics

Oruka Therapeutics, Inc (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company is focused on creating treatments that may provide durable disease control while reducing the frequency of administration compared with conventional biologic therapies.

Oruka’s pipeline is centered on engineered monoclonal antibodies that target the interleukin-17 (IL-17) pathway, an important driver of inflammation in conditions such as psoriasis and other autoimmune diseases.